FAM108C1 Inhibitors
FAM108C1 inhibitors constitute a class of chemical compounds designed to selectively interfere with the biochemical activity of the FAM108C1 protein. These inhibitors work by targeting specific domains or active sites within the FAM108C1 protein, leading to a reduction in its functional activity. The inhibitory action is highly specific and is predicated on the precise understanding of the protein's structure and the critical role it plays in cellular signaling pathways. The inhibitors often mimic or compete with natural substrates or cofactors that the FAM108C1 protein would typically interact with, thereby disrupting its normal function. By binding to the active or allosteric sites of FAM108C1, these inhibitors can prevent the protein from performing its catalytic activity or from interacting with other proteins, which is essential for its role in cellular processes. The specificity of these inhibitors is critical as it ensures minimal off-target effects, allowing for a more directed approach in studies focusing on the protein's function and behavior in various biological contexts.
The development of FAM108C1 inhibitors is a sophisticated process that requires a deep understanding of the protein's role in intracellular signaling as well as its interaction with other cellular components. These inhibitors are characterized by their ability to modulate the signaling pathways in which FAM108C1 is involved without affecting the upstream or downstream proteins in any significant way. This selective inhibition is crucial for elucidating the specific contributions of FAM108C1 to these pathways. The chemical structures of these inhibitors are often complex, reflecting the intricate nature of the protein's active sites, and are designed to achieve a high binding affinity and specificity. The action of these compounds sheds light on the dynamic nature of FAM108C1's function, providing valuable insights into how its activity affects cellular homeostasis and the regulation of signaling networks. Through the use of these inhibitors, researchers can dissect the protein's role and potentially uncover novel aspects of its function that are not yet fully understood.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin targets mTOR (mammalian target of rapamycin) which is a downstream effector in the PI3K/AKT pathway. As FAM108C1 is involved in cellular growth processes, inhibition of mTOR could indirectly result in the decreased activity of FAM108C1 by limiting cellular growth signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it leads to downregulation of the PI3K/AKT/mTOR pathway, which would decrease FAM108C1 activity due to reduced cellular proliferation and survival signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another inhibitor of PI3K. It operates similarly to LY294002 by inhibiting the PI3K/AKT/mTOR signaling pathway, potentially reducing FAM108C1 activity through decreased cellular growth and survival signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway. The MAPK/ERK pathway is implicated in various cellular processes including growth and differentiation, which could indirectly affect FAM108C1 activity by altering cellular context. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, components of the MAPK/ERK pathway. Inhibition of this pathway could reduce the activity of FAM108C1 by impacting cellular growth-related signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. By inhibiting JNK, the cellular response to stress and inflammation that could activate FAM108C1 is diminished. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK may result in reduced FAM108C1 activity by affecting cellular responses to stress and cytokines. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits AKT, which is a critical component of the PI3K/AKT/mTOR pathway. Inhibition of AKT would downregulate survival and growth signals, potentially decreasing FAM108C1 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can indirectly lead to the decreased activity of FAM108C1 by disrupting the degradation of proteins that negatively regulate cellular proliferation and survival pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor with targets that include RAF, which is part of the MAPK/ERK signaling pathway. By inhibiting RAF, sorafenib can decrease the activity of FAM108C1 by altering the cellular growth and differentiation signals. | ||||||